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Abstract
There has recently been significant interest in the concept of directly targeting intestinal phosphate transport to control
hyperphosphatemia in patients with chronic kidney disease. However, we do not have a complete understanding of the cellular
mechanisms that govern dietary phosphate absorption. Studies in the 1970s documented both active and passive pathways for
intestinal phosphate absorption. However, following the cloning of the intestinal SLC34 cotransporter, NaPi-IIb, much of the
research focused on the role of this protein in active transcellular phosphate absorption and the factors involved in its regulation.
Generation of a conditional NaPi-IIb knockout mouse has demonstrated that this protein is critical for the maintenance of skeletal
integrity during periods of phosphate restriction and that under normal physiological conditions, the passive sodium-independent
pathway is likely be the more dominant pathway for intestinal phosphate absorption. The review aims to summarise the most
recent developments in our understanding of the role of the intestine in phosphate homeostasis, including the acute and chronic
renal adaptations that occur in response to dietary phosphate intake. Evidence regarding the overall contribution of the transcel-
lular and paracellular pathways for phosphate absorption will be discussed, together with the clinical benefit of inhibiting these
pathways for the treatment of hyperphosphatemia in chronic kidney disease.
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Introduction
The regulation of phosphate homeostasis is achieved via com-
plex interactions between the kidney, intestine and bone, and
several endocrine factors [7]. It is widely accepted that the
kidneys play the major role in maintaining extracellular phos-
phate concentrations within their narrow limits. Consequently,
the majority of the research focus with regard to understand-
ing the cellular mechanisms and regulation of phosphate trans-
port has concentrated on the processes that occur in the prox-
imal tubule.
Historically, less is known about the cellular pathways that
govern intestinal phosphate absorption. However, with the
desire to develop novel drugs to diminish dietary phosphate
absorption in patients with chronic kidney disease (CKD),
there has been renewed interest in understanding the processes
involved in intestinal phosphate handling. In particular, the
generation of a conditional knockout mouse for the intestinal
SLC34 cotransporter, NaPi-IIb, has revealed some significant
and unexpected insights into the role of this protein in intesti-
nal phosphate absorption and phosphate homeostasis. This
review aims to present evidence that NaPi-IIb is critical for
intestinal phosphate absorption during periods of phosphate
restriction or during ontogenesis, but that during adulthood
under normal physiological conditions, the sodium-
independent pathway would play a more dominant role.
Intestinal phosphate absorption
Studies in the 1970s, using the triple-lumen perfusion tech-
nique in healthy volunteers, reported that the jejunum had a
higher phosphate transport rate than the ileum and that in the
jejunum, transport could be resolved into sodium-dependent
and sodium-independent components [30, 65]. This regional
profile for phosphate absorption was comparable to the obser-
vations described in rats in the same decade and led to the
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conclusion that intestinal phosphate absorption occurred pre-
dominately in the proximal small intestine [64]. In 2005, this
assumption was questioned when it was shown that in mice,
phosphate absorption occurs maximally in the ileum [51]. At
this time, studies demonstrated that the profile for phosphate
absorption in each rodent species broadly relates to the region-
al expression of NaPi-IIb [21, 44, 51]. Taken together with the
knowledge that the major regulators of intestinal phosphate
absorption (dietary phosphate and 1,25-dihydroxyvitamin
D3) induce alterations in protein levels of NaPi-IIb [23, 51],
it was widely accepted to be the main sodium-dependent in-
testinal phosphate transporter, and it played a significant role
in intestinal phosphate absorption [18, 21, 54].
Over the past 10 years, the role of NaPi-IIb in intesti-
nal phosphate absorption and phosphate homeostasis has
been intensely investigated. While it is still considered to
be the major phosphate transporter present at the
enterocyte brush border membrane (BBM), likely account-
ing for 90% of transcellular sodium-dependent transport
[54], there are emerging reports documenting the presence
of SLC20 proteins at this cellular location [3, 11, 21]. In
rats, PiT1 and more recently PiT2 proteins have been
reported to be present in intestinal regions with a high
absorptive capacity for phosphate [11, 21]. In mice, PiT2
has been detected in the ileum, but the regional profile has
not been established [52]. There are conflicting reports as
to whether PiT1 is regulated by dietary phosphate intake.
Giral et al. were unable to demonstrate any change in
protein levels after 7 days of a low-phosphate diet, while
Candeal et al. showed a small but significant increase in
abundance in the duodenum, but not jejunum, after 5 days,
with a more robust change occurring in both segments
after 10 days. The reason for this discrepancy is unclear
given that both studies used male rats (Sprague Dawley
vs. Wistar, respectively) of comparable age that were fed
diets with the same phosphate content. The most likely
explanation for the differences is that long-term phosphate
restriction is required for substantial changes in the levels
of this protein to occur [12, 21]. Levels of PiT2 protein
also appear to adapt to changes in dietary phosphate con-
tent, but these changes occur more rapidly than PiT1 and
mirror the time course for changes in NaPi-IIb [12]. While
these studies demonstrate that SLC20 levels are regulated
by dietary phosphate intake, proof for a functional role
of these proteins in intestinal phosphate absorption is
lacking. Controversially, although Candeal and col-
leagues documented changes in both SLC34 and
SLC20 proteins in response to altered dietary phosphate,
they propose that an additional sodium-dependent trans-
port system plays a major role in intestinal phosphate
absorption under certain conditions [12]. However, the
exact identity of this system and physiological relevance
remains unknown.
The overall contribution of the sodium-dependent ver-
sus sodium-independent components of intestinal phos-
phate absorption remains a constant debate. In 1977,
Walling demonstrated that there was a linear relationship
between phosphate absorption and intraluminal phosphate
concentrations at values above 1 mmol/L [64]. Similar
findings were reported by others at this time [65, 67]
and were interpreted that phosphate absorption was prob-
ably an active process at values below 1 mmol/L and that
passive absorption would occur at higher luminal concen-
trations. Of significance was the statement by Walton and
Grey that ‘Our results are entirely consistent with this
hypothesis but not sufficient to prove it’ [65]. Thirty years
on, we are now only just amassing sufficient evidence to
substantiate this hypothesis. Importantly, the cloning of
NaPi-IIb in 1998 [26] led researchers to focus on this
transporter, and combined with the use of experimental
approaches and phosphate concentrations to favour this
transport pathway, it was concluded that this was the dom-
inant route for intestinal phosphate absorption [18, 21,
54]. However, we now know that phosphate concentra-
tions present in the bulk phase of the intestinal contents
are in the millimolar range [16, 29, 35, 48]. Recent results
from studies utilising these concentrations to evaluate
phosphate transport in rats [48], NaPi-IIb knockout mice
[29] and Caco-2 cells [11] have promoted the consensus
that sodium-independent transport is indeed likely to be
dominant under normal physiological conditions.
Cloning and tissue expression of NaPi-IIb
A full-length cDNA of SLC34A2 was first identified in
1998 from a mouse embryo EST clone and was shown to
have a high homology (73%) to mouse NaPi-IIa, particu-
larly in the regions that represent transmembrane segments
[26]. The gene was detected in mouse small intestine,
colon, lung, kidney and testis [26], and in humans, it
was subsequently detected at high levels in lung, salivary
glands, mammary glands and small intestine [49]. It is
now known that constitutive deletion of the SLC34A2
gene in mice is embryonically lethal [58].
The cloned sequence codes for a 697 amino acid pro-
tein, with a molecular weight of 108 kDa for the glyco-
sylated form commonly detected in adult mouse small
intestine [26]. Partially glycosylated NaPi-IIb (~ 88 kDa)
has been reported in 14-day-old mouse intestine, with the
suggestion that full glycosylation occurs at the point of
transition between suckling and weaning [4]. As previous-
ly discussed, the profile for NaPi-IIb expression in the
small intestine shows significant species differences, but
regardless of the intestinal region, the protein is localised
to the enterocyte BBM along the entire length of the villus
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[21, 23, 26]. Interestingly, using autoradiography, it has
been shown that phosphate uptake, at least at luminal
phosphate concentrations that favour NaPi-IIb-mediated
transport, is restricted to the mid-upper regions of the villi
[45]. The difference between NaPi-IIb protein expression
pattern and its function is probably a consequence of the
time required for full functional expression of the protein
during enterocyte migration and maturation along the vil-
lus and the development of the electrochemical gradient
required for phosphate uptake.
NaPi-IIb is localised in tissues other than the small in-
testine. In the lung, the protein is restricted to the apical
membrane of alveolar type II cells and is thought to be
required for surfactant production [56, 63]. Mutations in
SLC34A2 are associated with pulmonary alveolar
microlithiasis [55], and recently, dysregulation of NaPi-
IIb has been implicated in tumorigenesis and progression
of non-small cell lung cancer [66]. In human salivary
glands, NaPi-IIb is found in both the parotid and subman-
dibular glands, where it has been localised to the
basolateral membrane of acini and the apical membrane
of duct cells and is proposed to be involved in phosphate
secretion and reabsorption, respectively [27]. Although
not usually associated with renal phosphate handling, the
protein has been reported to be localised to the basolateral
membrane of the collecting duct and/or the ascending limb
of the loop of Henle, and levels are upregulated in re-
sponse to a high-phosphate diet [60]. The proposed func-
tion of NaPi-IIb in these tubular segments is to aid phos-
phate excretion during high dietary phosphate intake; this
however requires clarification [60].
Functional characterisation of NaPi-IIb
in intestinal phosphate absorption
Characterisation of NaPi-IIb in Xenopus oocytes revealed this
protein to be a high-affinity sodium-dependent phosphate
cotransporter with an apparent Km for phosphate of ~
50 μmol/L and a Km for sodium of ~ 30 mmol/L [26]. It has
been shown to be exclusively sodium-dependent, to preferen-
tially transport divalent phosphate and to be electrogenic
translocating one net positive charge per transport cycle due
to the 3:1 Na+:Pi stoichiometry [19]. Given the observation
that phosphate uptake using intestinal BBM vesicles has sim-
ilar characteristics, with an affinity for phosphate of ~
0.1 mmol/L [6, 43], it was concluded that NaPi-IIb was the
protein responsible for the sodium-dependent component of
intestinal phosphate absorption.
Many researchers, myself included, subsequently used
0.1 mmol/L phosphate to favour NaPi-IIb-mediated transport
when investigating the mechanisms involved in the regulation
of intestinal phosphate absorption. These studies revealed that
a low-phosphate diet and 1,25-dihydroxyvitamin D3 are the
major regulators in intestinal phosphate absorption [23, 31]. In
response to chronic dietary phosphate restriction, upregulation
of mRNA and protein levels of NaPi-IIb occur in the jejunum
[21] and ileum [14, 51] of rats and mice, respectively, and
these alterations correlate with functional changes in absorp-
tion [21, 51]. Based on these findings, it is clear that active
transcellular phosphate absorption adapts in response to re-
duced oral phosphate intake and that it is likely that this path-
way is dominant under these conditions (Fig. 1b). In contrast,
when luminal phosphate concentrations increase following
ingestion of a phosphate-rich diet, NaPi-IIb will be function-
ing at its maximal rate and the luminal phosphate gradient will
instead favour the paracellular pathway (Fig. 1a). In this con-
text, dietary phosphate restriction would not only increase
NaPi-IIb-mediated transport but also lower the gradient for
passive transport across the epithelium, prompting a rapid
switch from the dominance of one pathway to the other [36].
Importantly, the idea that NaPi-IIb-mediated transport is only
dominant during dietary restriction is not new. In 1977,
Walling commented that their unpublished observations in
adult rats maintained on an adequate phosphate intake showed
no active absorption of phosphate by any gut segment [64].
Intestinal phosphate absorption in NaPi-IIb
knockout mice
The idea that NaPi-IIb may not be the dominant pathway
under normal dietary phosphate conditions is also supported
by recent studies using mice with intestinal ablation of NaPi-
IIb. When fed a standard diet (0.6–0.8% phosphate), NaPi-
IIb−/− mice have only moderate faecal phosphate wasting
[25, 54, 57]. In addition, NaPi-IIb+/− mice fed on a 0.8%
phosphate diet show no change in faecal phosphate excretion,
even though NaPi-IIb mRNA and protein levels and sodium-
dependent phosphate uptake measured using BBM vesicles
are decreased by more than half [25]. In line with the
suggestion that NaPi-IIb is functionally more dominant
during dietary phosphate restriction, maintenance of
NaPi-IIb−/− mice on a low (0.1%)-phosphate diet results
in an overall 40–45% increase in faecal phosphate excre-
tion relative to wild-type animals [36], while, importantly,
NaPi-IIb−/− mice maintained on a high (0.9–1.2%)-phos-
phate diet show either no significant increase [29], or a
decrease [36], in faecal phosphate excretion compared to
wild-type mice on the same diet, demonstrating the larger
contribution of passive transport after consumption of a
high-phosphate load.
Studies utilising changes in post-prandial serum phosphate
levels to access the acute impact of NaPi-IIb ablation on in-
testinal phosphate absorption also suggest a relatively small
role of NaPi-IIb. In experiments designed to maximise the
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potential contribution of the protein, Sabbagh et al. maintained
NaPi-IIb−/− mice on a low (0.02%)-phosphate diet for 1 week
prior to exposure to an acute phosphate load. In these exper-
iments, there was only a 50% reduction in post-prandial phos-
phate absorption compared to wild-type animals [54]. The
authors acknowledge that their estimates of NaPi-IIb-
mediated transport likely represent the maximal potential con-
tribution and that under normal dietary phosphate intake, the
overall percentage of active NaPi-IIb-mediated transport to
post-prandial phosphate absorption is likely to be lower.
Similar findings are also evident from in vitro transport studies
using different phosphate concentrations in the uptake buffer
to compare the overall contribution of sodium-dependent and
sodium-independent phosphate transport across the intesti-
nal epithelium. From these studies, it is clear that intestinal
ablation of NaPi-IIb in mice abolishes sodium-dependent
phosphate uptake into ileal BBM vesicles by 95% [25] and
in ileal everted sac’s by 90% [54], when using 0.1 mmol/L
and 1.2 mmol/L phosphate, respectively. However, recent
studies, also using the everted sac technique, but evaluat-
ing phosphate absorption at 4 mmol/L, suggest that there is
no significant difference in sodium-dependent or sodium-
independent phosphate transport between wild-type and
knockout animals, in contrast to transport measured at








































Fig. 1 Potential adaptations in intestinal phosphate absorption in
response to changes in dietary phosphate intake, or treatment with
phosphate binders or the NHE3 inhibitor, tenapanor. a Ingestion of a
normal or high-phosphate diet provides a luminal phosphate gradient that
favours the paracellular pathway, with NaPi-IIb likely functioning at its
maximal rate. Renal adaption occurs in response to the high dietary phos-
phate intake in order to maintain phosphate homeostasis [25, 51]. b In
contrast, during ingestion of a low-phosphate diet, the luminal phosphate
gradient is reduced and the contribution of the paracellular pathway di-
minishes. NaPi-IIb protein levels increase and this pathway becomes the
dominant route for phosphate absorption [51]. Studies from NaPi-IIb−/−
mice suggest that the adaptation in NaPi-IIb is required to protect bone
during phosphate restriction [36]. c Phosphate binders reduce the luminal
phosphate concentration and therefore the gradient for paracellular phos-
phate absorption. Recent studies in NaPi-IIb−/− mice have shown a po-
tential compensatory upregulation in NaPi-IIb following sevelamer treat-
ment [54]. d Tenapanor has been proposed to reduce paracellular phos-
phate absorption via changes in trans-epithelial electrical resistance.
Interestingly, the inhibitor also induces a downregulation in NaPi-IIb
protein levels as a means of preventing compensation by this pathway
[34]. The basolateral pathway responsible for phosphate efflux from the
enterocyte is unknown and whether it adapts during these conditions
requires investigation
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Is sodium-independent intestinal phosphate
absorption transcellular or paracellular?
It is still unclear whether the sodium-independent pathway for
phosphate absorption occurs via the paracellular or transcellu-
lar route. Early studies demonstrated that the pathway is mea-
surable not only in vivo but also when using BBM vesicles. At
this time, the sodium-independent pathway was shown not to
be regulated by 1,25-dihydroxyvitamin D3 or chronic dietary
phosphate adaptation [31, 39]. However, increased sodium-
independent phosphate transport has recently been reported
using BBM vesicles prepared from rats acutely switched from
a low- to high-phosphate diet [11]. In addition, in the human
Caco2BBE intestinal cell line, phosphate transport has been
proposed to be solely sodium-independent, that it is promoted
by high levels of phosphate in the growth medium, a response
which is mainly caused by changes in Vmax of the transport
process and depends on de novo RNA and protein synthesis
[11]. Taken together, these results suggest that there may be a
transcellular component to sodium-independent phosphate
absorption.
An alternative, and perhaps a more accepted consensus, is
that sodium-independent phosphate transport occurs via the
paracellular route. Claudins are integral to tight junction func-
tion, permitting or preventing paracellular transport through
their sealing or pore-forming characteristics [2, 22]. A number
of the pore-forming claudins have cation or anion selectivity
or are permeable to water [22], with evidence linking claudin-
2, claudin-12 and claudin-15 to paracellular calcium absorp-
tion in the small intestine (reviewed in [1]). Whether specific
tight junction proteins are involved in modulating paracellular
phosphate absorption is currently not known. However, recent
studies using tenapanor provided strong evidence for a link
between tight junction function and phosphate permeability.
This small-molecule inhibitor of the sodium/hydrogen ex-
changer (NHE3) acts locally in the gastrointestinal tract to
inhibit sodium absorption, but also significantly reduces intes-
tinal phosphate absorption in healthy volunteers [34] and im-
proves hyperphosphatemia in both rodents and humans with
CKD [8, 37]. It has been suggested to induce conformational
changes in the tight junctions, as a result of intracellular proton
retention caused by NHE3 inhibition, leading to increased
trans-epithelial electrical resistance (TEER) and thus a reduc-
tion in permeability to phosphate. Importantly, tenapanor also
decreases the expression of NaPi-IIb to prevent compensation
by the transcellular route [34] (Fig. 1d).
While King et al. propose that conformational changes
within the tight junction complexes, rather than changes in
the levels or localisation of specific claudins, affect
paracellular phosphate permeability in response to tenapanor
[34], it is interesting to note that alterations in mRNA and
protein levels of both pore-forming and sealing claudins occur
in the proximal and distal small intestine of NaPi-IIb−/− mice
[29]. Ikuta et al. speculate that these changes might influence
sodium-independent phosphate transport but do not defini-
tively associate them with adaptation in transport per se. It is
however plausible that alteration in tight junction composition
occurs to compensate for the reduced transcellular phosphate
absorption. Such a phenomenon has been reported in mice
lacking calbindin D9k, the intestinal calcium-binding protein
critical for transcellular calcium absorption, where overex-
pression of claudins 2 and 12 has been proposed to compen-
sate for the insufficient transcellular absorption [28].
NaPi-IIb and the gut-renal axis
In 2007, Berndt et al. provided evidence for an active role for
the intestine in the maintenance of phosphate homeostasis.
They proposed that a gut-derived factor was released in re-
sponse to ingestion of dietary phosphate and that this factor
rapidly modulated renal phosphate reabsorption to prevent
large post-prandial fluctuations in serum phosphate levels
[5]. The so called ‘intestinal phosphatonin’ was suggested to
act independently of changes in plasma phosphate concentra-
tion or parathyroid hormone (PTH) [5]. The finding that ma-
trix extracellular phosphoglycoprotein (MEPE), a protein typ-
ically secreted from bone [53] that has a phosphaturic effect
on the kidney [59], is present in the intestinal epithelium,
specifically the duodenum [3, 47], led to the suggestion that
this may be the factor proposed by Berndt et al. [47].
However, subsequent studies were unable to confirm the ex-
istence of this intestinal phosphatonin, but instead found that
acute renal adaptation to an oral phosphate load requires PTH
[40, 62]. With regard to MEPE, it is interesting to note that a
recent study has demonstrated that uremic rats maintained on
a high-phosphate diet have significantly increased levels of
intestinal MEPE expression. Since MEPE inhibits jejunal
phosphate absorption [46], it is possible that instead of acting
as an endocrine hormone, it may directly inhibit dietary phos-
phate absorption in an autocrine or paracrine fashion, thus
preventing acute changes in post-prandial phosphate levels
following ingestion of a high-phosphate load.
Other evidence in support of the existence of a gut-renal
axis comes from experiments using NaPi-IIb−/− mice. These
demonstrate that chronic impairment of intestinal phosphate
transport activates compensatory renal reabsorption in order to
maintain phosphate homeostasis [25, 29, 50, 54]. The first
publication documenting this effect used male mice main-
tained on a 0.6% phosphate diet and concluded that the reduc-
tion in urinary phosphate excretion was a consequence of
increased NaPi-IIa protein levels brought about by a decrease
in the levels of the osteocyte-derived phosphaturic hormone,
FGF-23 [54]. Subsequent studies have confirmed that NaPi-
IIb ablation prompts compensatory reductions in urinary
phosphate excretion but have provided conflicting results
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regarding the mechanism responsible. In adult male NaPi-
IIb−/− mice maintained on a 0.8% or 0.9% phosphate diet,
there is no change in intact FGF-23 levels [25, 50], NaPi-IIa
protein expression [25, 29, 50] or sodium-dependent transport
activity [25, 29], even though the mice have the expected
decrease in urinary phosphate excretion. In contrast, adult fe-
male and 4-week-old male NaPi-IIb−/− mice maintained on a
0.8% or 0.9% phosphate diet have a reduction in circulating
FGF-23 and elevated NaPi-IIa protein levels [25, 50]. The
reason for the difference in response to gender, age and levels
of dietary phosphate is not known. It is possible that there are
different thresholds to trigger the degree of compensatory re-
nal change depending on the long-term phosphate status and
that when phosphate demand is highest, this induces the FGF-
23/NaPi-IIa response to maximally enhance phosphate reab-
sorption with the aim of preserving phosphate balance.
Alternatively, or perhaps as part of the above mechanism, it
has been suggested that the more dominant renal effect seen in
females than males maybe due to differences in the proteolytic
processing of FGF-23 [25].
Finally, in context of the sodium-independent pathway,
NaPi-IIb−/− mice fed a high 1.2% phosphate diet have signif-
icantly elevated phosphaturia in comparison to those main-
tained on a 0.8% phosphate diet [36]. Although this is slightly
lower compared to wild-type mice on the same diet, it does
again demonstrate that the non-saturable route for phosphate
absorption is dominant during phosphate loading. As expect-
ed, the phosphaturia in both wild-type and knockout mice is
associated with elevated FGF-23 and PTH levels and a reduc-
tion in 1,25 dihydroxyvitamin D3, with no significant differ-
ence between the two groups [36]. Therefore, although it has
been suggested that NaPi-IIb could act as a sensing molecule
regulating the release of the unknown gut-derived
phosphaturic factor, it is more plausible based on the above
observations that both acute and chronic gut-renal interactions
are dependent on endocrine factors balancing renal phosphate
reabsorption to match intestinal phosphate absorption.
Is NaPi-IIb a suitable target to control
hyperphosphatemia in chronic kidney
disease?
Current strategies to control hyperphosphatemia in CKD pa-
tients include dietary phosphate restriction and the use of
phosphate binders. These approaches are often associated
with poor patient compliance due to the high-phosphate con-
tent of the typical Western diet, and the frequent dosing and
thus large pill burden, and often significant gastrointestinal
intolerance, caused by phosphate binders [13, 15]. In addition,
given the likely dominant role of NaPi-IIb when intestinal
phosphate concentrations are low, these strategies may even
favour dietary phosphate absorption. Indeed, mice with
adenine-induced CKD that are treated with the phosphate
binder sevelamer have elevated NaPi-IIb levels (Fig. 1c).
This adaptation was used to explain why binder treatment
was less effective in wild-type mice compared to uremic
NaPi-IIb−/− mice, where treatment completely attenuated the
hyperphosphatemia associated with renal insufficiency [57].
The observation that NaPi-IIb ablation in uremic mice
causes a sustained decrease, although not always complete
normalisation, of serum phosphate levels [50, 57] was used
to support the idea that NaPi-IIb is a suitable treatment target
for preventing or reducing hyperphosphatemia in CKD pa-
tients. Furthermore, niacin and its derivative nicotinamide,
proposed inhibitors of the type II phosphate transporter family
[32, 68], also have a positive impact on hyperphosphatemia in
rodents [17] and humans with CKD and ESRD (reviewed in
[20, 41]), although their use is associated with some adverse
effects that potentially preclude their clinical use [24, 42].
These observations led to the development of ASP3325, a
specific small-molecule NaPi-IIb inhibitor, which in several
rat models was shown to alleviate CKD-induced
hyperphosphatemia [61]. Unfortunately, subsequent clinical
studies failed to provide evidence that ASP3325 influences
urinary phosphate or faecal phosphate excretion in normal
healthy individuals, or that it reduces serum phosphate levels
in those with ESRD [38]. This lack of efficacy was suggested
to be a result of either a small or negligible role of NaPi-IIb in
humans [38]. However, the puzzle remains as to why niacin
and nicotinamide effectively lower serum phosphate levels in
CKD and ESRD patients if NaPi-IIb does not play a major
role in phosphate absorption in humans. Larsson et al. sug-
gested that it may be that these compounds offer a superior
target engagement compared to ASP3325, or that their
phosphate-lowering capacity may be caused by other pleiotro-
pic effects [38]. An alternative explanation and mode of action
for nicotinamide may be similar to that reported for tenapanor
[34], that it acts on tight junctions to reduce paracellular phos-
phate absorption and induces a decrease in NaPi-IIb expres-
sion to prevent compensation by the transcellular pathway.
Role of NaPi-IIb in bone development
and skeletal integrity
The skeleton acts as a large reservoir for phosphate, contain-
ing approximately 80% of total body phosphate; this is pri-
marily found complexed with calcium in the form of hydroxy-
apatite crystals [9]. In healthy adults, bone formation is in
balance with bone resorption; however, during infancy and
adolescence, the skeletal phosphate requirement is elevated
to allow for rapid bone development and growth. In this con-
text, it is well documented that in rats, intestinal phosphate
absorption is highest during suckling and weaning and that
the age-related decline in absorption correlates with decreased
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gene and protein levels of NaPi-IIb [4, 10, 69]. A critical role
for NaPi-IIb during ontogenesis is also supported by studies in
NaPi-IIb+/−mice. At 4 weeks of age, these mice have impaired
intestinal phosphate transport and hypophosphatemia, while
in contrast, at 20 weeks of age when the skeletal demand for
phosphate is not as high, the compensatory reduction in uri-
nary phosphate excretion seen in both age groups of NaPi-
IIb+/− mice is sufficient to maintain normal serum phosphate
concentrations [50].
It should, however, be noted that NaPi-IIb+/− mice show
comparable weight gain and growth as their wild-type litter-
mates, suggesting that either the residual NaPi-IIb present in
the intestine is sufficient to provide enough phosphate for
normal skeletal development, or that another pathway for ab-
sorption also contributes to the phosphate supply. In keeping
with the latter suggestion, early studies by Borowitz and
Ghishan investigating the impact of age on intestinal phos-
phate transport documented higher rates of sodium-
independent as well as sodium-dependent phosphate trans-
ports in younger animals [10]. Therefore, although current
evidence highlights the importance of NaPi-IIb in intestinal
phosphate transport during ontogenesis, the role of the sodi-
um-independent pathway perhaps deserves reinvestiga-
tion given that the high-phosphate content of the milk
consumed during suckling and weaning would generate
a favourable gradient for passive transport across the
intestinal epithelium.
In addition to the role for NaPi-IIb in intestinal phosphate
absorption during growth and development, the protein also
appears to be involved in maintaining bone integrity. Recent
studies by Knopfel et al. have shown that NaPi-IIb−/− and
wild-type mice maintained for 2 weeks on a low-phosphate
diet have normal serum phosphate and almost no urinary
phosphate excretion. However, in NaPi-IIb−/− mice, there is
exaggerated calcium excretion, lower bone mineral density
and a higher number of osteoclasts, leading to the suggestion
that bone resorption may be enhanced in NaPi-IIb−/−
mice releasing both calcium and phosphate at the cost
of bone mass loss [36]. Therefore, NaPi-IIb appears to
be important in protecting bone, particularly during
long-term phosphate restriction.
Bone disease and extra-skeletal calcification are considered
to be key characteristics of CKD-mineral bone disorder [33].
Studies investigating the role for NaPi-IIb in bone health dur-
ing CKD have shown that treatment of uremic NaPi-IIb−/−
mice with sevelamer provides significant phosphate control
and that this is associated with improvements in bone
histomorphometric parameters [57]. Importantly, these effects
were not as pronounced in sevelamer-treated wild-type mice,
or untreated knockout mice, perhaps reflecting roles for
both the sodium-dependent and sodium-independent
phosphate absorption pathways in the management of
bone disease in CKD.
Summary
Following the cloning of NaPi-IIb 20 years ago, its molecular
characteristics and regulation were investigated in detail.
However, more recently, knowledge of the phosphate concen-
trations present in the intestinal lumen, the generation of a
conditional NaPi-IIb knockout mouse and the development
of novel inhibitors of phosphate transport have provided us
with a more comprehensive understanding of the role of NaPi-
IIb in intestinal phosphate absorption and phosphate homeo-
stasis. There is a growing consensus that at dietary phosphate
levels seen in the typical Western diet, NaPi-IIb would be
saturated and paracellular transport would be the dominant
route for phosphate absorption. In contrast, consumption of
a diet low in phosphate would not only increase NaPi-IIb
protein levels but also lower the gradient for passive transport
across the epithelium, prompting a switch from the dominance
of one pathway to the other. The importance of NaPi-IIb in
phosphate homeostasis is however highlighted by the finding
that it protects bone during dietary phosphate restriction.
There are also intriguing new observations that claudin
proteins are altered following NaPi-IIb ablation. It is possible
that changes in the levels of these tight junction proteins may
evoke compensatory modifications to paracellular phosphate
absorption in response to reduced transcellular transport. In
this context, inhibition of the paracellular pathway with the
NHE3 inhibitor, tenapanor, also causes NaPi-IIb downreg-
ulation, presumably to prevent compensatory absorption
by this pathway. Whether there are common cellular
mechanisms regulating these two potentially interlinked
pathways remains to be seen.
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